Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 3/20 | 0.35 |
| ▸ | OTUD7B | Q6GQQ9 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803495 | 0.93 | ICMT (0.35) | ALOX5ICMTOTUD7BUSP30BACE1 | |
| SCHEMBL332241 | 0.89 | ICMT (0.33) | ICMTOTUD7BUSP30NAAA | |
| SCHEMBL3660567 | 0.88 | ALOX5 (0.46) | ALOX5ICMTOTUD7BPIK3CDUSP30 | |
| SCHEMBL332739 | 0.77 | ALOX5 (0.38) | ALOX5OTUD7BNAAA | |
| SCHEMBL12156883 | 0.77 | ALOX5 (0.38) | ALOX5OTUD7BNAAA | |
| SCHEMBL333246 | 0.76 | ALOX5 (0.46) | ALOX5ICMTOTUD7BUSP30NAAA | |
| SCHEMBL333249 | 0.74 | ALOX5 (0.45) | ALOX5PIK3CDHDAC4ABL1AKT1 | |
| SCHEMBL332891 | 0.73 | — | — | |
| SCHEMBL332725 | 0.71 | ALOX5 (0.53) | ALOX5OTUD7BPIK3CDUSP30NAAA | |
| SCHEMBL331664 | 0.70 | ALOX5 (0.55) | ALOX5PIK3CDHDAC4ABL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171445-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2013019926-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-02-07 | — | — | WO | disclosed |
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | ALOX5 1/4885ICMT 3459/4885OTUD7B 3963/4885 |
| US-20140171445-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | ALOX5, ALOX15, ALOX15B | ALOX5 1/4885ICMT 635/4885OTUD7B 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.